Soluble lytic transglycosylase SLT of Francisella novicida is involved in intracellular growth and immune suppression
Autoři:
Takemasa Nakamura aff001; Takashi Shimizu aff001; Akihiko Uda aff002; Kenta Watanabe aff001; Masahisa Watarai aff001
Působiště autorů:
Joint Faculty of Veterinary Medicine, Laboratory of Veterinary Public Health, Yamaguchi University, Yamaguchi, Japan
aff001; Department of Veterinary Science, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan
aff002
Vyšlo v časopise:
PLoS ONE 14(12)
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pone.0226778
Souhrn
Francisella tularensis, a category-A bioterrorism agent causes tularemia. F. tularensis suppresses the immune response of host cells and intracellularly proliferates. However, the detailed mechanisms of immune suppression and intracellular growth are largely unknown. Here we developed a transposon mutant library to identify novel pathogenic factors of F. tularensis. Among 750 transposon mutants of F. tularensis subsp. novicida (F. novicida), 11 were isolated as less cytotoxic strains, and the genes responsible for cytotoxicity were identified. Among them, the function of slt, which encodes soluble lytic transglycosylase (SLT) was investigated in detail. An slt deletion mutant (Δslt) was less toxic to the human monocyte cell line THP-1 vs the wild-type strain. Although the wild-type strain proliferated in THP-1 cells, the number of intracellular Δslt mutant decreased in comparison. The Δslt mutant escaped from phagosomes during the early stages of infection, but the mutant was detected within the autophagosome, followed by degradation in lysosomes. Moreover, the Δslt mutant induced host cells to produce high levels of cytokines such as tumor necrosis factor-α, interleukin (IL)-6, and IL-1β, compared with the wild-type strain. These results suggest that the SLT of F. novicida is required for immune suppression and escape from autophagy to allow its survival in host cells.
Klíčová slova:
Transposable elements – Cytokines – Autophagic cell death – Cytotoxicity – Immune suppression – Intracellular pathogens – Francisella tularensis – Francisella
Zdroje
1. Ellis J, Oyston PC, Green M, Titball RW. Tularemia. Clin Microbiol Rev. 2002;15(4):631–46. doi: 10.1128/CMR.15.4.631-646.2002 12364373
2. Carvalho CL, Lopes de Carvalho I, Ze-Ze L, Nuncio MS, Duarte EL. Tularaemia: a challenging zoonosis. Comp Immunol Microbiol Infect Dis. 2014;37(2):85–96. Epub 2014/02/01. doi: 10.1016/j.cimid.2014.01.002 24480622.
3. McLendon MK, Apicella MA, Allen LA. Francisella tularensis: taxonomy, genetics, and Immunopathogenesis of a potential agent of biowarfare. Annu Rev Microbiol. 2006;60:167–85. Epub 2006/05/18. doi: 10.1146/annurev.micro.60.080805.142126 16704343
4. Maurin M. Francisella tularensis as a potential agent of bioterrorism? Expert Rev Anti Infect Ther. 2015;13(2):141–4. doi: 10.1586/14787210.2015.986463 25413334.
5. Kingry LC, Petersen JM. Comparative review of Francisella tularensis and Francisella novicida. Front Cell Infect Microbiol. 2014;4:35. doi: 10.3389/fcimb.2014.00035 24660164
6. Clemens DL, Lee BY, Horwitz MA. Virulent and avirulent strains of Francisella tularensis prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages. Infect Immun. 2004;72(6):3204–17. doi: 10.1128/IAI.72.6.3204-3217.2004 15155622
7. Clemens DL, Lee BY, Horwitz MA. Francisella tularensis enters macrophages via a novel process involving pseudopod loops. Infect Immun. 2005;73(9):5892–902. doi: 10.1128/IAI.73.9.5892-5902.2005 16113308
8. Golovliov I, Baranov V, Krocova Z, Kovarova H, Sjöstedt A. An attenuated strain of the facultative intracellular bacterium Francisella tularensis can escape the phagosome of monocytic cells. Infect Immun. 2003;71(10):5940–50. doi: 10.1128/IAI.71.10.5940-5950.2003 14500514
9. Nano FE, Zhang N, Cowley SC, Klose KE, Cheung KK, Roberts MJ, et al. A Francisella tularensis pathogenicity island required for intramacrophage growth. J Bacteriol. 2004;186(19):6430–6. doi: 10.1128/JB.186.19.6430-6436.2004 15375123
10. Bröms JE, Sjöstedt A, Lavander M. The role of the Francisella tularensis pathogenicity island in type VI secretion, intracellular survival, and modulation of host cell signaling. Front Microbiol. 2010;1:136. doi: 10.3389/fmicb.2010.00136 21687753
11. Clemens DL, Ge P, Lee BY, Horwitz MA, Zhou ZH. Atomic structure of T6SS reveals interlaced array essential to function. Cell. 2015;160(5):940–51. doi: 10.1016/j.cell.2015.02.005 25723168
12. Gillette DD, Curry HM, Cremer T, Ravneberg D, Fatehchand K, Shah PA, et al. Virulent Type A Francisella tularensis actively suppresses cytokine responses in human monocytes. Front Cell Infect Microbiol. 2014;4:45. Epub 2014/05/02. doi: 10.3389/fcimb.2014.00045 24783062
13. Suzuki J, Uda A, Watanabe K, Shimizu T, Watarai M. Symbiosis with Francisella tularensis provides resistance to pathogens in the silkworm. Sci Rep. 2016;6:31476. doi: 10.1038/srep31476 27507264
14. Dik DA, Marous DR, Fisher JF, Mobashery S. Lytic transglycosylases: concinnity in concision of the bacterial cell wall. Crit Rev Biochem Mol Biol. 2017;52(5):503–42. Epub 2017/06/24. doi: 10.1080/10409238.2017.1337705 28644060
15. Scheurwater E, Reid CW, Clarke AJ. Lytic transglycosylases: bacterial space-making autolysins. Int J Biochem Cell Biol. 2008;40(4):586–91. Epub 2007/05/01. doi: 10.1016/j.biocel.2007.03.018 17468031.
16. Koraimann G. Lytic transglycosylases in macromolecular transport systems of Gram-negative bacteria. Cell Mol Life Sci. 2003;60(11):2371–88. Epub 2003/11/20. doi: 10.1007/s00018-003-3056-1 14625683.
17. Nagle SC Jr., Anderson RE, Gary ND. Chemically defined medium for the growth of Pasteurella tularensis. J Bacteriol. 1960;79:566–71. 14425793
18. Mc Gann P, Rozak DA, Nikolich MP, Bowden RA, Lindler LE, Wolcott MJ, et al. A novel brain heart infusion broth supports the study of common Francisella tularensis serotypes. J Microbiol Methods. 2010;80(2):164–71. doi: 10.1016/j.mimet.2009.12.005 20005265.
19. Pavlov VM, Mokrievich AN, Volkovoy K. Cryptic plasmid pFNL10 from Francisella novicida-like F6168: the base of plasmid vectors for Francisella tularensis. FEMS Immunol Med Microbiol. 1996;13(3):253–56. doi: 10.1111/j.1574-695X.1996.tb00247.x 8861039.
20. Rodriguez SA, Yu JJ, Davis G, Arulanandam BP, Klose KE. Targeted inactivation of Francisella tularensis genes by group II introns. Appl Environ Microbiol. 2008;74(9):2619–26. doi: 10.1128/AEM.02905-07 18310413
21. Shimizu T, Otonari S, Suzuki J, Uda A, Watanabe K, Watarai M. Expression of Francisella pathogenicity island protein intracellular growth locus E (IglE) in mammalian cells is involved in intracellular trafficking, possibly through microtubule organizing center. Microbiologyopen. 2019;8(4):e00684. Epub 2018/07/07. doi: 10.1002/mbo3.684 29978561
22. Bröms JE, Meyer L, Sun K, Lavander M, Sjöstedt A. Unique substrates secreted by the type VI secretion system of Francisella tularensis during intramacrophage infection. PLoS One. 2012;7(11):e50473. doi: 10.1371/journal.pone.0050473 23185631
23. Santin YG, Cascales E. Domestication of a housekeeping transglycosylase for assembly of a Type VI secretion system. EMBO Rep. 2017;18(1):138–49. Epub 2016/12/07. doi: 10.15252/embr.201643206 27920034
24. Putzova D, Panda S, Hartlova A, Stulik J, Gekara NO. Subversion of innate immune responses by Francisella involves the disruption of TRAF3 and TRAF6 signalling complexes. Cell Microbiol. 2017;19(11). Epub 2017/07/27. doi: 10.1111/cmi.12769 28745813.
25. Ireland PM, LeButt H, Thomas RM, Oyston PC. A Francisella tularensis SCHU S4 mutant deficient in gamma-glutamyltransferase activity induces protective immunity: characterization of an attenuated vaccine candidate. Microbiology. 2011;157(Pt 11):3172–9. Epub 2011/08/20. doi: 10.1099/mic.0.052902-0 21852349.
26. Balzano PM, Cunningham AL, Grassel C, Barry EM. Deletion of the Major Facilitator Superfamily Transporter fptB Alters Host Cell Interactions and Attenuates Virulence of Type A Francisella tularensis. Infect Immun. 2018;86(3). Epub 2018/01/10. doi: 10.1128/IAI.00832-17 29311235
27. Zahrl D, Wagner M, Bischof K, Bayer M, Zavecz B, Beranek A, et al. Peptidoglycan degradation by specialized lytic transglycosylases associated with type III and type IV secretion systems. Microbiology. 2005;151(Pt 11):3455–67. Epub 2005/11/08. doi: 10.1099/mic.0.28141-0 16272370.
28. Hoppner C, Carle A, Sivanesan D, Hoeppner S, Baron C. The putative lytic transglycosylase VirB1 from Brucella suis interacts with the type IV secretion system core components VirB8, VirB9 and VirB11. Microbiology. 2005;151(Pt 11):3469–82. Epub 2005/11/08. doi: 10.1099/mic.0.28326-0 16272371.
29. Crepin S, Ottosen EN, Peters K, Smith SN, Himpsl SD, Vollmer W, et al. The lytic transglycosylase MltB connects membrane homeostasis and in vivo fitness of Acinetobacter baumannii. Mol Microbiol. 2018;109(6):745–62. Epub 2018/06/10. doi: 10.1111/mmi.14000 29884996
30. Cloud-Hansen KA, Peterson SB, Stabb EV, Goldman WE, McFall-Ngai MJ, Handelsman J. Breaching the great wall: peptidoglycan and microbial interactions. Nat Rev Microbiol. 2006;4(9):710–6. Epub 2006/08/09. doi: 10.1038/nrmicro1486 16894338.
31. Bao Y, Tian M, Li P, Liu J, Ding C, Yu S. Characterization of Brucella abortus mutant strain Delta22915, a potential vaccine candidate. Vet Res. 2017;48(1):17. Epub 2017/04/06. doi: 10.1186/s13567-017-0422-9 28376905
32. Rohde M, Puls J, Buhrdorf R, Fischer W, Haas R. A novel sheathed surface organelle of the Helicobacter pylori cag type IV secretion system. Mol Microbiol. 2003;49(1):219–34. Epub 2003/06/26. doi: 10.1046/j.1365-2958.2003.03549.x 12823823.
33. Checroun C, Wehrly TD, Fischer ER, Hayes SF, Celli J. Autophagy-mediated reentry of Francisella tularensis into the endocytic compartment after cytoplasmic replication. Proc Natl Acad Sci U S A. 2006;103(39):14578–83. doi: 10.1073/pnas.0601838103 16983090
34. Chong A, Wehrly TD, Child R, Hansen B, Hwang S, Virgin HW, et al. Cytosolic clearance of replication-deficient mutants reveals Francisella tularensis interactions with the autophagic pathway. Autophagy. 2012;8(9):1342–56. doi: 10.4161/auto.20808 22863802
35. Yamamoto M, Takeda K. Current views of toll-like receptor signaling pathways. Gastroenterol Res Pract. 2010;2010:240365. Epub 2011/01/05. doi: 10.1155/2010/240365 21197425
36. Jones CL, Napier BA, Sampson TR, Llewellyn AC, Schroeder MR, Weiss DS. Subversion of host recognition and defense systems by Francisella spp. Microbiol Mol Biol Rev. 2012;76(2):383–404. Epub 2012/06/13. doi: 10.1128/MMBR.05027-11 22688817
37. Brewer SM, Brubaker SW, Monack DM. Host inflammasome defense mechanisms and bacterial pathogen evasion strategies. Curr Opin Immunol. 2019;60:63–70. Epub 2019/06/08. doi: 10.1016/j.coi.2019.05.001 31174046.
38. Fernandes-Alnemri T, Yu JW, Juliana C, Solorzano L, Kang S, Wu J, et al. The AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nat Immunol. 2010;11(5):385–93. Epub 2010/03/31. doi: 10.1038/ni.1859 20351693
39. Dotson RJ, Rabadi SM, Westcott EL, Bradley S, Catlett SV, Banik S, et al. Repression of inflammasome by Francisella tularensis during early stages of infection. J Biol Chem. 2013;288(33):23844–57. Epub 2013/07/04. doi: 10.1074/jbc.M113.490086 23821549
40. Hager AJ, Bolton DL, Pelletier MR, Brittnacher MJ, Gallagher LA, Kaul R, et al. Type IV pili-mediated secretion modulates Francisella virulence. Mol Microbiol. 2006;62(1):227–37. Epub 2006/09/22. doi: 10.1111/j.1365-2958.2006.05365.x 16987180.
41. Bachert BA, Biryukov SS, Chua J, Rodriguez SA, Toothman RG Jr., Cote CK, et al. A Francisella novicida Mutant, Lacking the Soluble Lytic Transglycosylase Slt, Exhibits Defects in Both Growth and Virulence. Front Microbiol. 2019;10:1343. Epub 2019/07/02. doi: 10.3389/fmicb.2019.01343 31258523
Článok vyšiel v časopise
PLOS One
2019 Číslo 12
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Nejasný stín na plicích – kazuistika
- MUDr. Dana Vondráčková: Hepatopatie sú pri liečbe metamizolom väčším strašiakom ako agranulocytóza
- Kombinace metamizol/paracetamol v léčbě pooperační bolesti u zákroků v rámci jednodenní chirurgie
- Metamizol v liečbe pooperačnej bolesti u detí do 6 rokov veku